Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mechanisms underlying agonist efficacy.

P G Strange1

  • 1School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AJ, UK. P.G.Strange@rdg.ac.uk

Biochemical Society Transactions
|July 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dopamine receptors in the brain and periphery: "state of the art".

Neurochemistry international·2010
Same author

The effect of tunicamycin on prostacyclin (PGI(2)) receptors of neuronal hybrid cells.

Neurochemistry international·2010
Same author

Monoclonal antibodies directed against the drug haloperidol.

Neurochemistry international·2010
Same author

Molecular neurobiology.

Neurochemistry international·2010
Same author

Cell surface receptors - Basic and clinical aspects.

Neurochemistry international·2010
Same author

Modelling the interdependence between the stoichiometry of receptor oligomerization and ligand binding for a coexisting dimer/tetramer receptor system.

British journal of pharmacology·2009
Same journal

TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis.

Biochemical Society transactions·2026
Same journal

Advancing the monitoring of organelle contact sites in vitro and in vivo.

Biochemical Society transactions·2026
Same journal

Mechanisms influencing transient cytoplasmic protein targeting to intracellular lipid droplets.

Biochemical Society transactions·2026
Same journal

Replication associated nuclear DNA mismatch repair across kingdoms.

Biochemical Society transactions·2026
Same journal

Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis.

Biochemical Society transactions·2026
Same journal

Implications of Rho GTPase signaling in cancer immunotherapy.

Biochemical Society transactions·2026
See all related articles

Agonist efficacy, a measure of receptor stimulation, is effectively determined using the guanosine 5'-[gamma-[(35)S]thio]triphosphate-binding assay. This method quantifies agonist efficacy by measuring bound ligand, not binding rate.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Molecular Biology

Background:

  • Agonist efficacy quantifies receptor response, with parameters like Emax and EC50 used for assessment.
  • The Emax.KA/EC50 parameter offers a comprehensive efficacy estimate.
  • G-protein-coupled receptor (GPCR) activation involves GTP binding, a process central to receptor signaling.

Purpose of the Study:

  • To detail the utility of the guanosine 5'-[gamma-[(35)S]thio]triphosphate ([(35)S]GTP[S])-binding assay for profiling agonist efficacy.
  • To elucidate the underlying mechanisms and kinetics of the [(35)S]GTP[S]-binding assay.
  • To establish an efficacy scale for the D2 dopamine receptor using this assay.

Main Methods:

  • Utilizing the [(35)S]GTP[S]-binding assay to measure agonist efficacy at receptors.

Related Experiment Videos

  • Employing functional assays to determine efficacy parameters such as Emax, KA/EC50, and Emax.KA/EC50.
  • Investigating the kinetics of [(35)S]GTP[S] binding to GPCRs.

    • Main Results:

    • The [(35)S]GTP[S]-binding assay provides a convenient method for assessing agonist efficacy.
    • The binding of [(35)S]GTP[S] to GPCRs follows pseudo-first-order kinetics, reaching equilibrium around 3 hours.
    • Agonists modulate the maximal level of [(35)S]GTP[S] bound, with this binding event being rate-limiting.
    • The assay determines efficacy based on the extent of [(35)S]GTP[S] binding, not the binding rate.

    Conclusions:

    • The [(35)S]GTP[S]-binding assay is a reliable tool for determining agonist efficacy, particularly for GPCRs.
    • Understanding the assay's kinetics confirms that maximal [(35)S]GTP[S] binding reflects agonist efficacy.
    • This assay facilitates the creation of efficacy scales, as demonstrated with the D2 dopamine receptor.